Epidemiological and Survival Trends in Patients of Cancer of Uterine Cervix Treated with Definitive Concurrent Chemoradiotherapy: Observations from a North Indian Hospital-Based Cancer Registry

Abstract

Worldwide, cervical cancer is the fourth most common cancer in women and a significant proportion of this cancer comes from India. Identifying various prognostic factors on survival outcomes will help us in giving better care and thereby prolonging life of these patients. Objective of this study was to assess various factors and their association with outcomes in terms of overall survival (OS) and disease-free survival (DFS) at 2 years and 5 years. This was a retrospective study carried out in a tertiary cancer care hospital. The data of 86 patients treated between November 2013 and November 2016 were retrospectively analyzed for OS and DFS using Kaplan–Meier survival curves. Association of various demographic and disease variables with OS and DFS was analyzed using Chi-square test. Among 86 patients included in the study, 84 (97.7%) were still alive at completed follow-up of 24 months and 77 (89.5%) were disease-free. At 5-year follow-up for 41 patients, 23 (56.1%) were alive and 21 (51.2%) were disease-free. Presence of pelvic lymphadenopathy and a hemoglobin of less than 10 mg/dl before or during treatment negatively impacted OS and DFS. OS and DFS rates in our practice are comparable to those in the published literature. Multiple treatment and disease variables can effect treatment outcomes and disease prognosis.